Clinical Trial

Rakovina Therapeutics Announces Private Placement Offering

The Company has received initial commitments totaling over $800,000 from strategic investors in connection with the OfferingVANCOUVER, British Columbia, Nov.…

1 year ago

Top NY Plastic Surgeon Dr. Rubinstein Chosen to Train New Advanced BOTOX(R) Cosmetic Technique for Platysma Bands After FDA Approval

Renowned expert Dr. Rubinstein to train practitioners on new BOTOX® technique for smoother neck contours in New York. NEWBURGH, NY…

1 year ago

COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

-Promising results obtained from the pre-clinical study with CollPlant's commercial sized rhCollagen-based regenerative breast implants, demonstrating significant implant vascularization and…

1 year ago

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

- Preselection Method for Cancers Responding to SLS009: High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers…

1 year ago

Prenetics Announces Third Quarter 2024 Financial Results

Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand…

1 year ago

Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives

SYDNEY, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic…

1 year ago

ALK’s pivotal phase 3 trial in children published in reputable scientific journal

The reputable scientific journal, The Lancet Regional Health – Europe, has published robust results from ALK’s house dust mite sublingual allergy…

1 year ago

Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…

1 year ago

NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update

TORONTO and HAIFA, Israel, Nov. 27, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the…

1 year ago